Genovate Biotechnology Co., Ltd. (TPEX:4130)

Market Cap	3.45B +28.5%
Revenue (ttm)	492.41M -3.6%
Net Income	11.68M -54.5%
EPS	0.10 -54.5%
Shares Out	113.75M
PE Ratio	295.53
Forward PE	n/a
Dividend	0.10 (0.32%)
Ex-Dividend Date	Aug 20, 2025

Volume	686,232
Average Volume	2,220,858
Open	31.00
Previous Close	30.35
Day's Range	30.55 - 31.45
52-Week Range	17.65 - 40.15
Beta	0.32
RSI	46.40
Earnings Date	Mar 27, 2026

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1982
• Employees: 190
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4130

Financial Performance

In 2025, Genovate Biotechnology's revenue was 492.41 million, a decrease of -3.61% compared to the previous year's 510.86 million. Earnings were 11.68 million, a decrease of -54.54%.